Scholar Rock Pharmaceuticals (SRRK) highlighted its aggressive timeline for FDA approval of apitegromab, a monoclonal antibody targeting spinal muscular atrophy (SMA), during its presentation at the September 2026 Cantor Fitzgerald Global Healthcare Conference. The drug’s U.S. Prescription Drug User Fee Act (PDUFA) action date looms on September 30, 2026, after the company received a Complete Response Letter (CRL) in November 2025 that cited manufacturing compliance concerns at its former fill-finish partner, Catalent Indiana. Following a Type C meeting with the FDA in March 2026, Scholar Rock secured an alternate facility, shifting the program to a dual-site “horse race” approach where either site could support approval. Catalent Indiana was later dropped from commercial manufacturing after the FDA reviewed alternate-site data, though it remains a clinical supplier for hundreds of patients. The company’s cash balance of nearly $500 million supports regulatory, commercial, and clinical initiatives, with a current ratio of 7.02 and a debt-to-equity ratio of 0.8, indicating solid liquidity and moderate leverage. The stock, trading near its 52-week high of $61.76, has delivered an 81.82% return over the past year, reflecting investor confidence in the pipeline’s potential.
Apitegromab is designed to address SMA, a rare neuromuscular disease affecting up to 35,000 patients globally, with the U.S. market alone estimated at 7,000 to 10,000 patients. The SMA market, valued at over $5 billion annually, is projected to exceed $7 billion within four to five years. The drug is positioned as a monthly intravenous infusion, with early access challenges expected in the first three to five quarters post-launch, as formulary integration and reimbursement hurdles unfold.
Scholar Rock’s Phase III SAPPHIRE trial, involving 188 patients, demonstrated clinically meaningful improvements in motor function, while its Phase II FORGE study in facioscapulohumeral muscular dystrophy (FSHD) has begun dosing. The company also plans to file with Japan’s PMDA by year-end 2026 without requiring a local clinical trial, aiming to commercialize apitegromab in up to 50 countries. Internationally, the European Medicines Agency (EMA) withdrew the Marketing Authorization Application (MAA) in August 2026 due to timing constraints, though the company is prepared to resubmit immediately upon clearance.
CEO David Hallal emphasized the FDA’s “horse race” strategy, allowing either manufacturing site to expedite approval. He noted that while reimbursement hurdles will present “speed bumps,” the company’s experience in overcoming similar barriers in prior therapies will guide its approach. The company’s broader pipeline includes SRK-439, a high-potency myostatin antibody, and additional rare neuromuscular disease indications such as Duchenne muscular dystrophy (DMD) and spinal and bulbar muscular atrophy (SBMA).
Scholar Rock’s financials remain robust, with a strong balance sheet and a focus on executing its regulatory and commercial strategy to advance apitegromab’s approval and market entry.
